GlassScriptPhysician profile
Michael L Cantwell
NPI 1750381059
$2,445.88
in general payments reported to CMS, 2019-2025
16 companies · $710 in 2025
The $710 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $90.92 · 2021: $86.40 · 2022: $361 · 2023: $515 · 2024: $477 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.34 |
| Education | $341.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $709.56 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $557.57 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $219.25 | 2022-2025 | Auvelity |
| Indivior INC. | $159.11 | 2019-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $155.47 | 2019-2025 | Abilify Maintena, Nuedexta, Rexulti |
| Abbvie INC. | $112.76 | 2022-2025 | Vraylar |
| Alkermes, INC. | $110.19 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.45 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $78.80 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $70.34 | 2025 | Fanapt |
| Lundbeck LLC | $46.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.73 | 2024-2025 | Cobenfy |
| Biogen, INC. | $28.51 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $20.73 | 2025 | Trintellix |
| Lilly USA, LLC | $14.71 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cantwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.